Lyfebulb: Connect people, Inspire change, Impact lives.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Lyfebulb: Connect people, Inspire change, Impact lives.
Released on: October 11, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Lyfebulb serves as a bridge between patients affected by chronic disease and companies that are developing products to help them.
  • Summary
  • Participants
  • Company
Lyfebulb serves as a bridge between patients affected by chronic disease and companies that are developing products to help them. Lyfebulb listens to the needs of patients, and communicates those needs, when identifying and working with companies. When patients have an entrepreneurial inclination, Lyfebulb encourages them to pursue their dreams. Our vision is to reduce patient disease burden by raising awareness for, partnering with and supporting innovative solutions that can be brought to market in the near future.
Dr. Hehenberger, MD, PhD is a leading medical and business expert in the biopharmaceutical industry and has more than 15 years of experience in leadership positions at JNJ, Eyetech pharmaceuticals, Coronado biosciences, and also as an investment professional at two large funds, Brummer and partners and Scandinavian Life Science Ventures. Her dedication to diabetes is reflected by her time on the senior team at the JDRF and conducting her post-doctorate at the Joslin Diabetes Center, Harvard Medical School. She received her MD and PhD at the Karolinska Institute in Stockholm, Sweden, where she retains a position with the Department of Endocrinology and Surgery. In 2014, she co-founded Lyfebulb, together with Mr Riccardo Braglia, CEO Helsinn and Dr Stephen Squinto, Venture partner Orbimed. Lyfebulb's overall Mission is to improve the quality of life for people living with chronic disease. Over the past 18 months, the founders have built a strong operational and governance team which execute on the Mission by identifying, raising awareness for, advising and capitalizing companies that can impact patients in the near term.
Lyfebulb was founded in 2014 by Dr. Karin Hehenberger, MD, PhD, and a Type 1 Diabetic. Lyfebulb’s mission is to Connect People, Inspire Change, and Impact lives. We are a patient empowerment platform, which centers around improving the lives of those impacted by chronic disease. Alongside a vibrant online presence including a website, blog, and social media platforms, Lyfebulb operates in two distinct ways: the Lyfebulb Social Club and Lyfebulb Cares. The Social Club hosts in person events that bring together people with chronic diseases, physicians, medical thought leaders, patient support organizations, media, investors and entrepreneurs, in informative and relaxed environments across Manhattan. The Social Club connects like-minded individuals and provides an interactive, non-clinical environment where guests can share experiences and learn about new therapies and technologies to help combat chronic illness. Lyfebulb Cares operates as a Venture Philanthropy fund that invests donor capital into entities with near term solutions that impact patients' quality of life NOW. Our investment guidelines begin by listening to patient needs, and spans sectors including healthcare products and services, consumer goods, mobile applications and other supportive care services. Lyfebulb invests only in companies that yield a "Triple Impact Return" of Patient, Social and Financial benefits; very often these same companies are those that we have collaborated with for our Social Club. We are here to help now!